2-Chlorodeoxyadenosine is a nucleoside analog that has a cytotoxic effect on both resting and dividing lymphocytes. It has an established activity in the treatment of indolent lymphoid malignancies, including mycosis fungoides (MF).1 At standard-dose levels, myelosuppression is the principal adverse effect, occurring in more than 50% of patients.2 Since no curative treatment for MF is available, systemic therapy should be chosen so as to be effective and palliative.3 Thus, the observed high rate of severe immunosuppression, together with a substantial risk for serious infection, prevents the use of 2-chlorodeoxyadenosine in larger series of patients with MF. According to a recent report, low-dose 2-chlorodeoxyadenosine retained comparable antitumor activity but caused fewer infections than the standard-dose regimen in the treatment of non-Hodgkin lymphoma.4 Since cutaneous T-cell lymphomas were not included in this series, we report the results of an early phase 2 study on the efficacy and the adverse effect profile of a low-dose regimen of 2-chlorodeoxyadenosine in the treatment of MF.
Trautinger F, Schwarzmeier J, Hönigsmann H, Knobler RM. Low-Dose 2-Chlorodeoxyadenosine for the Treatment of Mycosis Fungoides. Arch Dermatol. 1999;135(10):1279-1280. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-10-dlt1099